Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles
  • Search Articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Targeting tryptophan hydroxylase 1 restricts growth and suppresses plasticity in neuroendocrine prostate cancer
Jing Wei, Jing Wang, Jingrui Chen, Michelle Zhang, Chia-Hui Chen, Tianjie Pu, Alivia O’Brien, Sephtis Hargrove, Eva Corey, Tzu-Ping Lin, Allen C. Gao, Boyang Jason Wu
Jing Wei, Jing Wang, Jingrui Chen, Michelle Zhang, Chia-Hui Chen, Tianjie Pu, Alivia O’Brien, Sephtis Hargrove, Eva Corey, Tzu-Ping Lin, Allen C. Gao, Boyang Jason Wu
View: Text | PDF
Research Article Cell biology Oncology

Targeting tryptophan hydroxylase 1 restricts growth and suppresses plasticity in neuroendocrine prostate cancer

  • Text
  • PDF
Abstract

Advanced prostate cancer has increasingly developed a lethal neuroendocrine form, small cell/neuroendocrine prostate cancer (NEPC), as a consequence of the widespread use of highly potent androgen receptor signaling inhibitors in castration-resistant disease. The molecular mechanisms remain unclear and no effective therapies currently exist. We report that tryptophan hydroxylase 1 (TPH1), the enzyme responsible for peripheral serotonin biosynthesis — a neurotransmitter enriched in neuroendocrine tumors and a classical neuroendocrine biomarker — was upregulated in both de novo and therapy-induced human NEPC. TPH1 upregulation was necessary and sufficient for neuroendocrine differentiation and the NEPC phenotype through its enzymatic activity. Silencing TPH1 suppressed neuroendocrine plasticity and various aggressive behaviors of NEPC cells, including proliferation, invasion, sphere formation, and NEPC tumor xenograft growth. Mechanistically, TPH1 activated mTOR via intracellular serotonin-dependent serotonylation of mTOR at glutamine 2453, which triggered the induction of FOXM1 and E2F1 to drive NEPC differentiation and growth. Importantly, pharmacological inhibition of TPH1 using the clinically available inhibitor LX1606 effectively restricted growth and neuroendocrine marker expression in multiple NEPC cell lines and patient-derived xenografts. Collectively, these findings characterize TPH1’s contribution to NEPC and suggest TPH1 as a potential therapeutic target.

Authors

Jing Wei, Jing Wang, Jingrui Chen, Michelle Zhang, Chia-Hui Chen, Tianjie Pu, Alivia O’Brien, Sephtis Hargrove, Eva Corey, Tzu-Ping Lin, Allen C. Gao, Boyang Jason Wu

×

Figure 5

TPH1 activates mTOR through intracellular serotonin in NEPC cells.

Options: View larger image (or click on image) Download as PowerPoint
TPH1 activates mTOR through intracellular serotonin in NEPC cells.
(A) G...
(A) GSEA of the top 5 Hallmark gene sets positively enriched in TPH1-OE LNCaP cells. (B) Western blot of mTOR and related phosphoproteins in control and TPH1-manipulated PC cells. p-, phosphorylated. (C) Proliferation of control and TPH1-OE LNCaP cells with rapamycin (25 nM, 3 days) (n = 3). (D) Western blot of TPH1, p-mTOR, and NE markers in control and TPH1-OE LNCaP with rapamycin for 48 hours. (E) Proliferation of Dox-inducible TPH1-KD LASCPC-01 cells pretreated with rapamycin for 24 hours followed by Dox stimulation (100 ng/mL, 3 days) (n = 3), with the percentage of proliferation inhibition shown. (F) Western blot of TPH1, p-mTOR, p-4E-BP1, and NE markers in LASCPC-01 cells as in E. (G) Proliferation of control and TPH1-OE LNCaP cells with 10 μM asenapine (ASE), 2 μM sertraline (Setra), or TPH1 siRNA (n = 3). (H) Western blot of NE markers in control and TPH1-OE LNCaP cells under the same treatments as in G for 48 hours. (I) Representative IF staining and quantification of per-cell perinuclear intracellular serotonin in control and TPH1-OE LNCaP cells, with more than 350 cells per group. Scale bar: 20 μm. (J) Western blot of mTOR and downstream phosphoproteins in control and TPH1-OE LNCaP cells with ASE, Setra, or 200 μM MDC for 30 minutes. Data represent mean ± SEM. Statistics were calculated using 2-way ANOVA with Holm-Šídák test (C), unpaired 2-tailed Student’s t test (E and I), or 1-way ANOVA with Tukey’s test (G). **P < 0.01.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts